<DOC>
	<DOCNO>NCT03020160</DOCNO>
	<brief_summary>This multicenter , open-label , non-randomized study ass efficacy , safety , pharmacokinetics , pharmacodynamics emicizumab administer dose 6 milligram per kilogram ( mg/kg ) every 4 week participant hemophilia A without inhibitor factor VIII ( FVIII ) . The study consist 2 part : pharmacokinetic ( PK ) run-in part follow expansion part .</brief_summary>
	<brief_title>A Study Evaluate Efficacy , Safety , Pharmacokinetics , Pharmacodynamics Emicizumab Given Every 4 Weeks Participants With Hemophilia A</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Body weight great equal ( &gt; /= ) 40 kilogram ( kg ) screen Diagnosis severe congenital hemophilia A hemophilia A FVIII inhibitor Participants use rFVIIa willing switch recombinant activate factor VII ( rFVIIa ) primary bypass agent treatment breakthrough bleeds FVIII inhibitor test screen titer result available prior first administration study drug Participants without FVIII inhibitor , less ( &lt; ) 0.6 Bethesda unit per milliliter [ BU/mL ] , complete successful immune tolerance induction ( ITI ) must do least 5 year screen must evidence inhibitor recurrence ( permanent temporary ) indicate detection inhibitor great ( &gt; ) 0.6 BU/mL since ITI Adequate hematologic , hepatic , renal function Inherited acquire bleed disorder hemophilia A Ongoing plan ITI therapy ; participant ITI fail eligible 72hour washout period prior first emicizumab administration History illicit drug alcohol abuse within 48 week prior screen , investigator 's judgment Participants high risk thrombotic microangiopathy ( TMA ) ( example , previous medical family history TMA ) , investigator 's judgment Previous ( within last 12 month ) current treatment thromboembolic disease ( exception previous catheterassociated thrombosis antithrombotic treatment currently ongoing ) sign thromboembolic disease Other condition ( example , certain autoimmune disease ) may currently increase risk bleed thrombosis History clinically significant hypersensitivity associate monoclonal antibody therapy component emicizumab injection Known HIV infection cluster differentiation ( CD ) 4 cell count &lt; 200 cell per microliter ( cells/mcL ) Use systemic immunomodulators ( example , interferon ) enrollment plan use study , exception antiretroviral therapy Concomitant disease , condition , significant abnormality screen evaluation laboratory test , treatment could interfere conduct study , would , opinion investigator , pose additional unacceptable risk administer study drug participant Pregnancy lactation intention become pregnant study Women positive serum pregnancy test result within 7 day prior initiation study drug</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>